Platelet Transfusions

Initial results reported from analysis of phase III data for Intercept Blood System

Published in Blood Weekly, July 15th, 2004

Cerus Corporation (CERS) reported the initial results of an independent review and analysis of data from the previously reported phase III U.S. clinical trial for the Intercept Blood System for platelets, which is being developed to protect against transmission of infectious diseases through platelet transfusions.

The blinded review of data by an independent panel of experts was agreed upon with the U.S. Food and Drug Administration (FDA) as a next step in the U.S. regulatory submission for the Intercept Blood System for platelets.

The analysis of primary patient records performed under the direction of an independent contract research organization...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry